NCT00728650

Brief Summary

This study will review the treatment and outcomes of patients having primary and metastatic hepatic malignancies. Patients treated with surgical resection, percutaneous radiofrequency ablation (RFA), and transarterial chemoembolization (TACE) will be compared with patients not receiving these treatments. Tumor recurrence and survival data will be compared to the published literature to determine the efficacy of current treatment strategies in this patient population.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
228

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Oct 2003

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

October 1, 2003

Completed
4.8 years until next milestone

First Submitted

Initial submission to the registry

August 1, 2008

Completed
5 days until next milestone

First Posted

Study publicly available on registry

August 6, 2008

Completed
2.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 1, 2010

Completed
8 months until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2011

Completed
Last Updated

February 7, 2012

Status Verified

February 1, 2012

Enrollment Period

7 years

First QC Date

August 1, 2008

Last Update Submit

February 6, 2012

Conditions

Liver Cancer

Keywords

hepatocellular carcinomacolorectal carcinoma metastatic to liverprimary liver cancer

Outcome Measures

Primary Outcomes (1)

  • Survival

    lifetime

Secondary Outcomes (1)

  • Efficacy

    lifetime

Study Arms (1)

Observation

Patients with primary or metastatic hepatic malignancies

Eligibility Criteria

Age20 Years - 90 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Primary care clinic and patients treated at St. John Medical Center in Tulsa, OK

You may qualify if:

  • Patients with primary or metastatic hepatic malignancies

You may not qualify if:

  • Patients not diagnosed with primary or metastatic hepatic malignancies

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

The University of Oklahoma College of Medicine, Tulsa - Department of Surgery

Tulsa, Oklahoma, 74135, United States

Location

Related Publications (1)

  • Curley SA, Izzo F, Delrio P, Ellis LM, Granchi J, Vallone P, Fiore F, Pignata S, Daniele B, Cremona F. Radiofrequency ablation of unresectable primary and metastatic hepatic malignancies: results in 123 patients. Ann Surg. 1999 Jul;230(1):1-8. doi: 10.1097/00000658-199907000-00001.

    PMID: 10400029RESULT

MeSH Terms

Conditions

Liver NeoplasmsCarcinoma, Hepatocellular

Condition Hierarchy (Ancestors)

Digestive System NeoplasmsNeoplasms by SiteNeoplasmsDigestive System DiseasesLiver DiseasesAdenocarcinomaCarcinomaNeoplasms, Glandular and EpithelialNeoplasms by Histologic Type

Study Officials

  • Thomas A Broughan, MD

    University of Oklahoma-Tulsa

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

August 1, 2008

First Posted

August 6, 2008

Study Start

October 1, 2003

Primary Completion

October 1, 2010

Study Completion

June 1, 2011

Last Updated

February 7, 2012

Record last verified: 2012-02

Locations

US(1)